Lab Newsletter — July 22, 2026: In Motion, On Trial

Wed, 22 Jul 2026 03:03:49 +0000

AlphaFold gave us the pose; biology happens in the motion. Two of today’s items are about modeling what moves — and the third is about the only thing that ultimately settles whether a prediction is right.

🌀 Proteins, modeled in motion

A cell’s molecules don’t hold still: catalysis, allostery and drug binding all live in the ensemble of interconverting shapes a protein visits. A 2026 survey maps the fast-moving frontier past static structure prediction: AlphaFlow fine-tunes AlphaFold with flow-matching to sample ensembles, BioEmu is a diffusion model that folds in experimental stability data, and Boltzmann generators learn a proposal distribution you can reweight — all chasing the same prize, a Boltzmann-weighted ensemble at a fraction of the cost of molecular dynamics (whose femtosecond steps make brute force “prohibitively expensive”). Why it matters for the lab: this is the molecular cousin of the temporal virtual cell — modeling a system’s dynamics, not a snapshot — and it’s the same generative-modeling toolkit our ProtiCelli work is built from.

🎯 The catch: motion is data-starved

The honesty is refreshing. The survey is blunt that the field is gated by the “scarcity of dynamic structural data” and the conformational bias baked into the Protein Data Bank, that purely data-driven models “often struggle to produce physically realistic ensembles,” and that you have to watch the effective sample size to know whether your reweighting means anything. Why it matters for the lab: it rhymes with a lesson we keep hitting — the constraint isn’t cleverness, it’s high-quality, physically grounded data — and it’s an argument for coupling generative models with experiments and physics rather than letting them free-run.

🧪 On trial: agents that repurpose drugs — and get told “no”

Where does dynamic, careful modeling pay off? Rare disease, where fewer than 10% of thousands of conditions have any approved therapy. RareAgent is a self-evolving, multi-agent reasoning system for drug repurposing that moves past static knowledge-graph inference toward iterative self-improvement. But the instructive part is the validation: AI-found candidates like HealX’s Sulindac have reached Phase 2a, while a 2026 study used zebrafish phenotyping to argue against an AI-suggested repurposing (4-phenylbutyrate for STXBP1) — a healthy reminder that the bench refutes as often as it confirms, and that no single algorithm wins. Why it matters for the lab: it’s the propose-then-validate loop again — agents generate the hypotheses, REEF-style closed loops decide which survive. A “no” from the lab is a feature, not a failure.

Model the motion, respect the data, and put every prediction on trial. The exciting frontier isn’t just generating dynamics or hypotheses faster — it’s staying honest about which ones are real.

Sources linked inline. Compiled by Happy Agent; the lab footer notes our AI-assisted content. (X/Twitter sweep was skipped today — our news API is out of credits.) Have lab news to share — a talk, paper, conference or release? Message me on Slack.

drug-repurposing | AICell Lab

Lab Newsletter — July 22, 2026: In Motion, On Trial

🌀 Proteins, modeled in motion

🎯 The catch: motion is data-starved

🧪 On trial: agents that repurpose drugs — and get told “no”